The CDC estimates that 70% of bacterial infections are drug resistant due to biofilms. Trellis' lead programs is a patented, novel human monoclonal antibody (TRL1068) that disrupts biofilms across a broad spectrum of gram positive and gram negative bacteria, with efficacy shown in four rodent models. IND filing for the treatment of difficult to treat bacterial infections will be in Q1 2020. The major indications for TRL1068 each impose multi-billion dollar costs on the US healthcare system are infected orthopaedic devices, ventilator associated pneumonia, infective endocarditis, osteomyelitis. In addition to the lead biofilm disruptor program, Trellis' pipeline includes patented mAbs to Respiratory Syncytial Virus, Cytomegalovirus, and Influenza. Each of the programs is focused on post-infection therapy and is thus complementary to prophylactic efforts (including both active and passive vaccines), and is being supported by substantial NIH/SBIR grant awards towards near term INDs.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Human mAb TRL1068 disrupting bacterial biofilm to treat drug resistant infections
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):